• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

    2/26/25 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care
    Get the next $MDXH alert in real time by email

    Fourth quarter revenue growth of 28% to $24.7 million

    2024 revenue growth of 28% to $90.0 million

    68% improvement in adjusted EBITDA in fourth quarter

    Conference call with Q&A today at 4:30 PM EST / 22:30 CET

    IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024.

    Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our performance in Q4 underscores our commitment to deliver sustainable growth and puts us on track to achieve adjusted EBITDA profitability in the first half of this year. We continue to see strong adoption of our expanded menu of tests, and our commercial team is driving further penetration into our key urology market. With the pending draw of the second tranche under our OrbiMed debt facility, our balance sheet will be significantly strengthened to meet our 2025 earnout obligation to Exact Sciences as well as support the execution of our 2025 business plan. We are confident in our ability to deliver continued growth and deliver value to our stakeholders, including patients, customers and shareholders."

    Key Highlights:

    • 2024 revenue of $90.0 million, an increase of 28% over 2023
    • Fourth quarter revenue of $24.7 million, an increase of 28% over prior year period
    • Fourth quarter adjusted EBITDA of ($1.4) million, a 68% improvement over prior year period
    • Fourth quarter tissue-based (Confirm mdx and GPS) test volume of 11,789, an increase of 50% over prior year period
    • Fourth quarter liquid-based (Select mdx, Resolve mdx, Germline) test volume of 12,036, an increase of 10% over prior year period
    • Year-end cash and cash equivalents balance of $46.8 million

    Financial review for the fourth quarter and year ended December 31, 2024        

    USD in ‘000 (except per share data)

    Unaudited



     Three months ended

    December 31
     Twelve months ended

    December 31
     20242023% Change 20242023% Change
    Revenue 24,73919,39828% 90,04970,19328%
    Cost of goods (9,222)(6,727)37% (34,908)(26,264)33%
    Gross Profit 15,51712,67122% 55,14143,92926%
    Operating expenses (20,125)(18,977)6% (79,863)(71,256)12%
    Operating loss (4,608)(6,306)(27%) (24,722)(27,327)(10%)
    Net loss (6,841)(10,720)(36%) (38,069)(43,100)(12%)
    Adjusted EBITDA* (1,378)(4,371)(68%) (14,672)(19,382)(24%)
    Basic and diluted loss per share (0.14)(0.39)(64%) (1.16)(1.66)(30%)

    * A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Non-IFRS Measures"

    Fourth Quarter 2024 Financial Results

    Revenue increased 28% to $24.7 million compared to $19.4 million for the prior year period. Tissue-based tests accounted for 81% and 76% of total fourth quarter 2024 and 2023 revenue, respectively.

    Gross profit increased 22% to $15.5 million compared to $12.7 million for the prior year period. Gross margins were 62.7% compared to 65.3% for the prior year period, a decline of 2.6 percentage points primarily attributed to our test mix and timing of payments.

    Operating expenses increased 6% to $20.1 million compared to $19.0 million for the prior year period, primarily driven by increases in R&D expenses associated with clinical studies as well as increases in other operating expenses, partially offset by savings in G&A.

    Net loss decreased 36% to $6.8 million compared to $10.7 million for the year period, driven by our $2.8 million increase in gross profit as well as a decrease of $2.2 million in net financial expenses.

    Adjusted EBITDA was ($1.4) million, an improvement of 68% compared to ($4.4) million for the same period last year.

    A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Non-IFRS Measures."

    Full Year 2024 Financial Results

    Revenue increased 28% to $90.0 million compared to $70.2 million for the prior year. Tissue-based tests accounted for 80% and 79% of total 2024 and 2023 revenue, respectively.

    Gross profit increased 26% to $55.1 million compared to $43.9 million for the prior year. Gross margins were 61.2% compared to 62.6% for the prior year, a decline of 1.4 percentage points primarily attributed to our test mix.

    Operating expenses increased 12% to $79.9 million compared to $71.3 million for the prior year, primarily driven by increases in R&D expenses associated with clinical trials as well as increases in sales and marketing expenses related to our unit and revenues growth and the associated incentive compensation of our commercial sales team.

    Net loss decreased 12% to $38.1 million compared to $43.1 million for the prior year, driven by our $11.2 million increase in gross profit as well as a decrease of $2.8 million in net financial expenses.

    Adjusted EBITDA was ($14.7) million, an improvement of 24% compared to ($19.4) million for the same period last year.

    A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Non-IFRS Measures."

    Cash and cash equivalents as of December 31, 2024, were $46.8 million.

    Outlook for 2025

    The Company is maintaining its previously issued 2025 revenue guidance of $108-110 million and confirms its view of expected adjusted EBITDA profitability in the first half of 2025.



    Conference Call

    Michael K. McGarrity, Chief Executive Officer and Ron Kalfus, Chief Financial Officer, will host a conference call and Q&A session today at 4:30 PM EST / 22:30 CET. The call will be conducted in English and a replay will be available for 30 days.

    To participate in the conference call, please select your phone number below:

    United States: 1-844-825-9789

    Belgium: 0800 38 961

    The Netherlands: 0800 94 94 506

    United Kingdom: 0808 238 9064

    Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1706814&tp_key=e01537d9e2

    To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled

    start time.

    About mdxhealth

    Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

    Non-IFRS disclosure

    In addition to the Company's financial results determined in accordance with IFRS, the Company provides adjusted EBITDA, a non-IFRS measure that it determines to be useful in evaluating its operating performance. The Company defines adjusted EBITDA as net loss less interest expense, depreciation and amortization of intangible assets, share-based compensation, fair-value adjustments, debt extinguishment costs, amendments related to the Exact Sciences earnout, income tax benefit, and other financial and non-cash expenses. Management believes that presentation of non-IFRS financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. The Company uses this non-IFRS financial information to establish budgets, manage the Company's business, and set incentive and compensation arrangements. However, non-IFRS financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS. For example, non-IFRS adjusted EBITDA excludes a number of expense items that are included in net loss. As a result, positive adjusted EBITDA may be achieved while a significant net loss persists. The Company's presentation of expected non-IFRS adjusted EBITDA is a forward-looking statement about the Company's future financial performance. This non-IFRS measure includes adjustments like share-based compensation, debt extinguishment costs, fair-value adjustments related to contingent considerations that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Additionally, management does not forecast many of the excluded items for internal use. Information reconciling forward-looking non-IFRS measures to IFRS measures is therefore not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of the items excluded from IFRS to calculate non-IFRS could significantly impact the Company's IFRS results.

    This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "potential," "expect," "will," "goal," "next," "potential," "aim," "explore," "forward," "future," and "believes" as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding expected future operating results; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of our products and services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash will be sufficient to fund our future operating expenses and capital expenditure requirements; our ability to remain in compliance with financial covenants made to and make scheduled payments to our creditors; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the Oncotype DX® GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

    NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.



    MDxHealth SA and Subsidiaries

    UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

      Three Months Ended

    December 31,
      Year Ended

    December 31,
     
    In thousands of $ (except per share amounts) 2024  2023  2024  2023 
                 
    Revenues $ 24,739  $ 19,398  $ 90,049  $ 70,193 
    Cost of sales (exclusive of amortization of intangible assets)  (9,222)  (6,727)  (34,908)  (26,264)
    Gross profit  15,517   12,671   55,141   43,929 
    Research and development expenses  (2,788)  (1,829)  (10,552)  (6,376)
    Selling and marketing expenses  (9,701)  (9,484)  (40,981)  (36,915)
    General and administrative expenses  (5,865)  (6,730)  (22,801)  (23,010)
    Amortization of intangible assets  (1,330)  (1,127)  (4,905)  (4,494)
    Other operating (expense) income, net  (441)   193   (624)  (461)
    Operating loss  (4,608)  (6,306)  (24,722)  (27,327)
    Financial expenses, net  (2,185)  (4,413)  (12,965)  (15,772)
    Loss before income tax  (6,793)  (10,719)  (37,687)  (43,099)
    Income tax  (48)   (1)   (382)   (1) 
    Loss for the period  $(6,841)  $(10,720)  $(38,069)  $(43,100)
                     
    Loss per share attributable to parent                
    Basic and diluted  $(0.14)  $(0.39)  $(1.16)  $(1.66)



    UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

     In thousands of $   December 31,

    2024
      December 31,

    2023
     
    ASSETS        
    Non-current assets        
    Goodwill    $35,926   $35,926 
    Intangible assets    40,592   44,337 
    Property, plant and equipment    4,363   4,956 
    Right-of-use assets    8,617   4,989 
    Financial assets    936   763 
    Total non-current assets    90,434   90,971 
               
    Current assets          
    Inventories    3,869   2,779 
    Trade receivables    14,440   11,088 
    Prepaid expenses and other current assets    1,788   1,914 
    Cash and cash equivalents    46,798   22,380 
    Total current assets    66,895   38,161 
    TOTAL ASSETS    $157,329   $129,132 
               
    EQUITY          
    Share capital    $214,670   $173,931 
    Issuance premium    153,177   153,177 
    Accumulated deficit    (369,515)  (331,446)
    Share-based compensation    17,124   12,139 
    Translation reserve    (615)  (593)
    Total equity    14,841   7,208 
               
    LIABILITIES          
    Non-current liabilities          
    Loans and borrowings    50,967   35,564 
    Lease liabilities    7,413   3,578 
    Other non-current financial liabilities    41,445   63,259 
    Total non-current liabilities    99,825   102,401 
               
    Current liabilities          
    Loans and borrowings    324   643 
    Lease liabilities    1,360   1,480 
    Trade payables    8,001   8,811 
    Other current liabilities    6,567   5,694 
    Other current financial liabilities    26,411   2,895 
    Total current liabilities    42,663   19,523 
    Total liabilities    142,488   121,924 
    TOTAL EQUITY AND LIABILITIES    $157,329   $129,132 



    UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

        Year Ended December 31,  
    In thousands of $

    For the years ended December 31
       2024  2023  
    CASH FLOWS FROM OPERATING ACTIVITIES         
    Operating loss    $(24,722) $ (27,327) 
    Depreciation    3,134   2,365  
    Amortization of intangible assets    4,905   4,494  
    Share-based compensation    1,725   665  
    Other non-cash transactions    286   421  
    Cash used in operations before working capital changes    (14,672)  (19,382) 
                
    Increase (-) in inventories    (1,090)  (452)  
    Increase (-) in receivables    (3,226)  (1,683) 
    Increase (+) in payables    458   20  
    Net cash outflow from operating activities    (18,530)  (21,497) 
                
    CASH FLOWS FROM INVESTING ACTIVITIES           
    Purchase of property, plant and equipment    (1,188)  (2,747) 
    Acquisition and generation of intangible assets    (971)  (2,272)  
    Noviogendix milestone payment    (555)  -  
    Interests received    1,078   1,088  
    Net cash outflow from investing activities    (1,636)  (3,931) 
                
    CASH FLOWS FROM FINANCING ACTIVITIES           
    Proceeds from issuance of shares, net of transaction costs    40,739   39,599  
    Proceeds from loan obligation    53,011   -  
    Repayment of loan obligation and debt extinguishment costs    (39,540)  (1,659)  
    Amendment fee related to OrbiMed agreement    (550)     
    Amendment fee related to GPS asset purchase agreement    -   (250) 
    Payment of lease liability    (1,883)  (1,610) 
    Payment of interest    (6,702)  (3,610) 
    Other financial expenses    (477)  (190) 
    Net cash inflow from financing activities    44,598   32,280  
                
    Net increase in cash and cash equivalents    24,432   6,852  
                
    Cash and cash equivalents at beginning of the financial year    22,380   15,503  
    Effect on exchange rate changes    (14)  25  
    Cash and cash equivalents at end of the financial year    $46,798   $22,380  



    UNAUDITED RECONCILIATION OF IFRS TO NON-IFRS FINANCIAL MEASURES

      Three Months Ended

    December 31,
      Year Ended

    December 31,
     
    In thousands of $ 2024  2023  2024  2023 
                 
    IFRS net loss $ (6,841)  $ (10,720)  $ (38,069)  $ (43,100) 
    Amortization of intangible assets  1,330   1,127   4,905   4,494 
    Depreciation expense  863   455   3,134   2,365 
    Share-based compensation expense  666   208   1,725   665 
    Interest expense, net  1,589   1,064   6,551   4,494 
    Debt extinguishment costs  -   -   3,130   - 
    Fair value adjustments (1)  483   4,150   2,961   9,960 
    Exact Sciences earnout amendment (2)  -   (877)  -   1,128 
    Other adjustments (3)  484   221   609   611 
    Income tax  48   1   382   1 
    Adjusted EBITDA  $(1,378)  $(4,371)  $(14,672)  $(19,382)

    1)   Primarily related to GPS contingent consideration, Exact Sciences 5-year warrants, Innovatus derivative instrument, option to pay Exact Sciences earnout in shares, and Noviogendix contingent consideration

    2)   Amendment fee and issuance of shares as part of amended GPS asset purchase agreement

    3)   Bank fees and other non-cash expenses





    For more information: 

    [email protected]

    LifeSci Advisors (IR & PR)

    US: +1 949 271 9223

    [email protected]

    Attachment

    • MDXH FY2024 FINAL


    Primary Logo

    Get the next $MDXH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MDXH

    DatePrice TargetRatingAnalyst
    10/31/2024$7.00Buy
    Lake Street
    5/31/2023$7.00Outperform
    TD Cowen
    7/18/2022$18.00Outperform
    Oppenheimer
    More analyst ratings

    $MDXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on MDxHealth SA with a new price target

      Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00

      10/31/24 8:59:17 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • TD Cowen initiated coverage on MDxHealth SA with a new price target

      TD Cowen initiated coverage of MDxHealth SA with a rating of Outperform and set a new price target of $7.00

      5/31/23 7:34:28 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Oppenheimer resumed coverage on MDxHealth SA with a new price target

      Oppenheimer resumed coverage of MDxHealth SA with a rating of Outperform and set a new price target of $18.00

      7/18/22 9:23:47 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mvm Partners, Llc bought $4,000,000 worth of shares (1,000,000 units at $4.00)

      4 - MDxHealth SA (0001872529) (Issuer)

      2/28/23 4:22:02 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors

                  Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie

      7/8/24 8:00:00 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Resignation of Board Member

      Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert's resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity, CEO of mdxhealth, commented: "On behalf of the Board of Directors and the employees of mdxhealth, I would like to thank Jan for his suppor

      2/16/24 8:45:00 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Financials

    Live finance-specific insights

    See more
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our perfo

      2/26/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    SEC Filings

    See more
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      7/3/25 4:48:27 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      6/6/25 5:12:22 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      5/14/25 4:05:22 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      11/14/24 3:15:43 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MDxHealth SA

      SC 13D/A - MDxHealth SA (0001872529) (Subject)

      10/28/24 2:52:50 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      10/4/24 5:14:19 PM ET
      $MDXH
      Medical Specialities
      Health Care